Details
Title
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Author
Hurvitz, Sara A. 1
; Bardia, Aditya 2 ; Punie, Kevin 3 ; Kalinsky, Kevin 4
; Carey, Lisa A. 5
; Rugo, Hope S. 6
; Diéras, Véronique 7
; Phan, See 8 ; Delaney, Rosemary 8 ; Zhu, Yanni 8 ; Tolaney, Sara M. 9
1 Fred Hutchinson Cancer Center, Clinical Research Division, Department of Medicine, UW Medicine, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
2 Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
3 Leuven Cancer Institute and University Hospitals Leuven, Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
4 Emory University, Winship Cancer Institute, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
5 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA (GRID:grid.189967.8) (ISNI:0000 0004 0452 4880)
6 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA (GRID:grid.511215.3) (ISNI:0000 0004 0455 2953)
7 Centre Eugène Marquis, Rennes, France (GRID:grid.417988.b) (ISNI:0000 0000 9503 7068)
8 Gilead Sciences Inc., Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634)
9 Harvard Medical School, Dana-Farber Cancer Institute, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
; Bardia, Aditya 2 ; Punie, Kevin 3 ; Kalinsky, Kevin 4
; Carey, Lisa A. 5
; Rugo, Hope S. 6
; Diéras, Véronique 7
; Phan, See 8 ; Delaney, Rosemary 8 ; Zhu, Yanni 8 ; Tolaney, Sara M. 9
1 Fred Hutchinson Cancer Center, Clinical Research Division, Department of Medicine, UW Medicine, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
2 Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
3 Leuven Cancer Institute and University Hospitals Leuven, Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
4 Emory University, Winship Cancer Institute, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
5 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA (GRID:grid.189967.8) (ISNI:0000 0004 0452 4880)
6 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA (GRID:grid.511215.3) (ISNI:0000 0004 0455 2953)
7 Centre Eugène Marquis, Rennes, France (GRID:grid.417988.b) (ISNI:0000 0000 9503 7068)
8 Gilead Sciences Inc., Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634)
9 Harvard Medical School, Dana-Farber Cancer Institute, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
Pages
55
Publication year
2024
Publication date
2024
e-ISSN
23744677
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3077577911
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.